Mount Sinai - Experimental Therapeutics Institute

Strategic Plan

Experimental Therapeutics Institute

Mount Sinai School of Medicine's 12 translational research institutes are creating a research environment that encourages collaboration and rewards work that challenges conventional wisdom. Read about the Experimental Therapeutics Institute’s role.

View PDF

Additional Resource

Experimental Therapeutics Institute

Find Out More about this Institute.

Systems Pharmacology - Bioinformatics and Computational Core

The Bioinformatics and Computational Core of the ETI provides expertise in emerging interdisciplinary fields on the usage of databases, statistical analyses tools and model development analyses. The Systems Pharmacology Computational Core will provide data analysis services to assist investigators in placing their experimental data in context of other drugs and link results to known regulatory molecular pathways in mammalian cells and systems.

Chemical Screening Core

The Translational Chemical Biology Center provides research investigators at Mount Sinai access to small molecule chemical compounds that can be used as tools to advance discovery basic and translational research of human biology and disease and in drug discovery.

Pharmacokinetics and Pharmacodynamics Core

This core provides consultation in design and analysis of studies to determine pharmacokinetic characteristics and dose-response relationships of new therapeutic agents, the application of these findings, to the establishment of drug treatment regimens and the modification of regimens in response to genetic variability and drug-drug interactions.

About ETI

The Experimental Therapeutics Institute is a hub for the development of new drugs, devices, and intellectual property that result from Mount Sinai's basic and clinical research programs. Integrated research programs focus on small molecule drug discovery; biological therapeutics; therapeutic vaccine development; target validation and side effects; and preclinical testing. Institute investigators conduct scientific and commercial assessments of promising research and technology, perform preclinical testing, and foster commercial relationships with pharmaceutical and medical device companies.

An Integrated Approach

"The Experimental Therapeutics Institute enables Mount Sinai to integrate the many facets of therapeutics research, including small molecule drugs and gene- and cell-based therapeutics," said Ravi Iyengar, PhD, Director and the Dorothy H. and Lewis Rosenstiel Professor and Chair of the Department of Pharmacology and Systems Therapeutics, and Professor of Oncological Sciences and of Psychiatry. "It also brings the emerging technologies in these fields to all Mount Sinai researchers to evaluate and develop their discoveries into therapeutics for complex diseases."

Investigators work closely with many research programs, departments, and Institutes at Mount Sinai, including the Institute for Personalized Medicine, the Black Family Stem Cell Institute, and the Cancer Institute. "Our work requires collaborative and multidisciplinary approaches," said Ming-Ming Zhou, PhD, Co-Director and the Dr. Harold and Golden Lamport Professorship in Physiology and Biophysics, Professor and Chair of Structural and Chemical Biology, and Professor of Oncological Sciences and of Pharmacology and Systems Therapeutics.